Italian Group of Adult Hematological Diseases
This is a no-profit, multicenter, biological, non-pharmacologic study aimed to characterize from a biological point of view previously untreated primary ITP patients. To this end, peripheral blood, fecal and bone marrow samples will be collected at baseline and at 30 days and 180 days after treatment initiation - for each line of therapy - and the results of the biological analysis performed at each time point will then be compared.
Immune Thrombocytopenia
peripheral blood and bone marrow withdrawal
Not Applicable
This is a no-profit, multicenter, biological, non-pharmacologic study aimed to characterize from a biological point of view ITP patients. Patients with previously untreated primary ITP who need first-line therapy will be included in the study. To this end, peripheral blood, fecal and bone marrow samples will be collected at baseline and at 30 days and 180 days after treatment initiation. The same assessments will be repeated in case of any potential new line of therapy. The results of the biological analysis performed at each time point will then be compared, in order to seek changes related to the natural history of the disease, the therapy administered and the response achieved.}}
Study Type : | Interventional |
Estimated Enrollment : | 200 participants |
Masking : | None (Open Label) |
Primary Purpose : | Basic Science |
Official Title : | Biologic Characterization of Patients With Immune Thrombocytopenia (ITP) |
Actual Study Start Date : | March 2023 |
Estimated Primary Completion Date : | March 2026 |
Estimated Study Completion Date : | March 2026 |
Arm | Intervention/treatment |
---|---|
Other: Biological evaluation characterization of biological features of enrolled ITP patients |
Other: peripheral blood and bone marrow withdrawal |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.